• Principal Investigator
  • Male

Prof. dr. M. Nieuwdorp MD PhD

Position: Professor
Main activities: Research, Patient care
Specialisation: Internal medicine/Endocrinology
foto M. Nieuwdorp is one of the AMC Principal Investigators
Focus of research:

 

- role of gutmicrobiota in development of human obesity, insulin resistance and dyslipidemia
 

 

AMC themes: Cardiovascular Diseases, Metabolic disorders and gastrointestinal diseases
Departments: Experimental Vascular Medicine, Internal Medicine: Vascular Medicine
Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M, Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. GASTROENTEROLOGY 2017;152 (7):1671-1678 [PubMed]
de Clercq N, Frissen MN, Groen AK, Nieuwdorp M, GUT MICROBIOTA AND THE GUT-BRAIN AXIS: NEW INSIGHTS IN THE PATHOPHYSIOLOGY OF METABOLIC SYNDROME. PSYCHOSOM MED 2017;ahead of print [PubMed]
de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M, Fecal microbiota transplantation in metabolic syndrome: History, present and future. GUT MICROBES 2017;8 (3):253-267 [PubMed]
Groen AK, Nieuwdorp M, An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases. EMBO MOL MED 2017;9 (1):1-3 [PubMed]
Herrema H, Ijzerman RG, Nieuwdorp M, Emerging role of intestinal microbiota and microbial metabolites in metabolic control. DIABETOLOGIA 2017;60 (4):613-617 [PubMed]
König J, Siebenhaar A, Högenauer C, Arkkila P, Nieuwdorp M, Norén T, Ponsioen CY, Rosien U, Rossen NG, Satokari R, Stallmach A, de Vos W, Keller J, Brummer RJ, Consensus report: faecal microbiota transfer - clinical applications and procedures. ALIMENT PHARM THER 2017;45 (2):222-239 [PubMed]
ter Horst KW, Gilijamse PW, Versteeg RI, Ackermans MT, Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ, Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. CELL REP 2017;19 (10):1997-2004 [PubMed]
ter Horst KW, van Galen KA, Gilijamse PW, Hartstra AV, de Groot PF, van der Valk FM, Ackermans MT, Nieuwdorp M, Romijn JA, Serlie MJ, Methods for quantifying adipose tissue insulin resistance in overweight/obese humans. INT J OBESITY 2017;41 (8):1288-1294 [PubMed]
van Beurden YH, Nieuwdorp M, van de Berg PJEJ, Mulder CJJ, Goorhuis A, Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. THER ADV GASTROENTER 2017;10 (4):373-381 [PubMed]
Bernelot Moens SJ. Cardiovascular disease beyond traditional risk factors: Balancing lipids and inflammation. S.l.: s.n.; 2016. 253p. ISBN 9789462334588 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Stroes ESG, Nieuwdorp M; copromotor(s): Dallinga-Thie GM)
Bernelot Moens SJ, Stoekenbroek RM, van der Valk FM, Verweij SL, Koelemay MJW, Verberne HJ, Nieuwdorp M, Stroes ESG, Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. BMC CARDIOVASC DISOR 2016;16 (1):237 [PubMed]
de Clercq NC, Groen AK, Romijn JA, Nieuwdorp M, Gut Microbiota in Obesity and Undernutrition. ADV NUTR 2016;7 (6):1080-1089 [PubMed]
Hartstra AV, Nieuwdorp M, Herrema H, Interplay between gut microbiota, its metabolites and human metabolism: Dissecting cause from consequence. TRENDS FOOD SCI TECH 2016;57 (B):233-243
Jakulj L, van Dijk TH, de Boer JF, Kootte RS, Schonewille M, Paalvast Y, Boer T, Bloks VW, Boverhof R, Nieuwdorp M, Beuers UHW, Stroes ESG, Groen AK, Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion. CELL METAB 2016;24 (6):783-794 [PubMed]
Koopen AM, Groen AK, Nieuwdorp M, Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk. CURR OPIN LIPIDOL 2016;27 (6):615-622 [PubMed]
Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P, Durable coexistence of donor and recipient strains after fecal microbiota transplantation. SCIENCE 2016;352 (6285):586-589 [PubMed]
Reijnders D, Goossens GH, Hermes GDA, Neis EPJG, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS, Nieuwdorp M, Groen AK, Olde Damink SWM, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CHC, Blaak EE, Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. CELL METAB 2016;24 (2):341 [PubMed]
Reijnders D, Goossens GH, Hermes GDA, Neis EPJG, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS, Nieuwdorp M, Groen AK, Olde Damink SWM, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CHC, Blaak EE, Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. CELL METAB 2016;24 (1):63-74 [PubMed]
Scheithauer TPM, Dallinga-Thie GM, de Vos WM, Nieuwdorp M, van Raalte DH, Causality of small and large intestinal microbiota in weight regulation and insulin resistance. MOL METAB 2016;5 (9):759-770 [PubMed]
Smits LP, Coolen BF, Panno MD, Runge JH, Nijhof WH, Verheij J, Nieuwdorp M, Stoker J, Beuers UH, Nederveen AJ, Stroes ES, Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. RADIOLOGY 2016;278 (3):782-791 [PubMed]
Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, Nieuwdorp M, Groen AK, Cahen DL, van Raalte DH, Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. DIABETES OBES METAB 2016;18 (12):1217-1225 [PubMed]
ter Horst KW, Gilijamse PW, Ackermans MT, Soeters MR, Nieuwdorp M, Romijn JA, Serlie MJ, Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans. METABOLISM 2016;65 (5):757-763 [PubMed]
Udayappan S, Manneras-Holm L, Chaplin-Scott A, Belzer C, Herrema H, Dallinga-Thie GM, Duncan SH, Stroes ESG, Groen AK, Flint HJ, Backhed F, de Vos WM, Nieuwdorp M, Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ BIOFILMS MICROBIOMES 2016;2:16009 [PubMed]
van der Valk F. Translating lipid-driven infammation in atherosclerosis. S.l.: s.n.; 2016. 273p. ISBN 978-94-6299-418-8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Stroes ESG, Nieuwdorp M; copromotor(s): Nederveen AJ)
van der Valk FM, Bekkering S, Kroon J, Yeang C, van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LAB, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ESG, Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. CIRCULATION 2016;134 (8):611-624 [PubMed]
van Rooijen G, Denys D, Fliers E, Nieuwdorp M, Effective Electroconvulsive Therapy in a Patient With Psychotic Depression With Active Cushing Disease. J ECT 2016;32 (3):e20-e21 [PubMed]
Bakker GJ, Zhao J, Herrema H, Nieuwdorp M, Gut Microbiota and Energy Expenditure in Health and Obesity. J CLIN GASTROENTEROL 2015;49 (Suppl. 1):S13-S19 [PubMed]
Dallinga-Thie GM, Nieuwdorp M, GLP1, an Important Regulator of Intestinal Lipid Metabolism. ARTERIOSCL THROM VAS 2015;35 (5):1048-1049 [PubMed]
Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EMM, Brandt LJ, Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion. J CLIN GASTROENTEROL 2015;49 (Suppl. 1):S69-S73 [PubMed]
Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M, Insights into the role of the microbiome in obesity and type 2 diabetes. DIABETES CARE 2015;38 (1):159-165 [PubMed]
Lankelma JM, Nieuwdorp M, de Vos WM, Wiersinga WJ, The gut microbiota in internal medicine: implications for health and disease. NETH J MED 2015;73 (2):61-68 [PubMed]
Melgar S, Nieuwdorp M, Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?. GASTROENTEROLOGY 2015;149 (4):848-850 [PubMed]
Mooij HL. Functional consequences of inborn and acquired errors in endothelial glycocalyx heparan sulfates. S.l.: s.n.; 2015. 212p. ISBN 978-94-6182-547-6 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Stroes ESG, Vink H; copromotor(s): Nieuwdorp M, Dallinga-Thie GM)
Mooij HL, Bernelot Moens SJ, Gordts PLSM, Stanford KI, Foley EM, van den Boogert MAW, Witjes JJ, Hassing HC, Tanck MW, van de Sande MAJ, Levels JH, Kastelein JJP, Stroes ESG, Dallinga-Thie GM, Esko JD, Nieuwdorp M, Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. J LIPID RES 2015;56 (3):665-673 [PubMed]
Stoekenbroek RM, Rensing KL, Bernelot Moens SJ, Nieuwdorp M, DeVries JH, Zwinderman AH, Stroes ES, Currie CJ, Hutten BA, High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events. ATHEROSCLEROSIS 2015;240 (2):318-323 [PubMed]
ter Horst KW, Gilijamse PW, de Weijer BA, Kilicarslan M, Ackermans MT, Nederveen AJ, Nieuwdorp M, Romijn JA, Serlie MJ, Sexual Dimorphism in Hepatic, Adipose Tissue, and Peripheral Tissue Insulin Sensitivity in Obese Humans. FRONT ENDOCRINOL 2015;6:182 [PubMed]
ter Horst KW, Gilijamse PW, Koopman KE, de Weijer BA, Brands M, Kootte RS, Romijn JA, Ackermans MT, Nieuwdorp M, Soeters MR, Serlie MJ, Insulin resistance in obesity can be reliably identified from fasting plasma insulin. INT J OBESITY 2015;39 (12):1703-1709 [PubMed]
van der Valk FM, van Wijk DF, Lobatto ME, Verberne HJ, Storm G, Willems MCM, Legemate DA, Nederveen AJ, Calcagno C, Mani V, Ramachandran S, Paridaans MPM, Otten MJ, Dallinga-Thie GM, Fayad ZA, Nieuwdorp M, Schulte DM, Metselaar JM, Mulder WJM, Stroes ES, Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. NANOMED-NANOTECHNOL 2015;11 (5):1039-1046 [PubMed]
van Nood E. Fecal Microbiota Transplantation: Clinical and experimental studies. S.l.: s.n.; 2015. 234p. ISBN 978-90-6464-842-7 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Speelman P; copromotor(s): Keller JJ, Dijkgraaf MGW, Nieuwdorp M)
van Olden C, Groen AK, Nieuwdorp M, Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus. CLIN THER 2015;37 (6):1172-1177 [PubMed]
Witjes JJ, van Raalte DH, Nieuwdorp M, About the gut microbiome as a pharmacological target in atherosclerosis. EUR J PHARMACOL 2015;763 (Part A):75-78 [PubMed]
Bernelot Moens SJ, Mooij HL, Hassing HC, Kruit JK, Witjes JJ, van de Sande MAJ, Nederveen AJ, Xu D, Dallinga-Thie GM, Esko JD, Stroes ESG, Nieuwdorp M, Carriers of loss-of-function mutations in EXT display impaired pancreatic beta-cell reserve due to smaller pancreas volume. PLOS ONE 2014;9 (12):e115662 [PubMed]
Fryer LGD, Jones B, Duncan EJ, Hutchison CE, Ozkan T, Williams PA, Alder O, Nieuwdorp M, Townley AK, Mensenkamp AR, Stephens DJ, Dallinga-Thie GM, Shoulders CC, The endoplasmic reticulum coat protein II transport machinery coordinates cellular lipid secretion and cholesterol biosynthesis. J BIOL CHEM 2014;289 (7):4244-4261 [PubMed]
Hassing HC, Surendran RP, Derudas B, Verrijken A, Francque SM, Mooij HL, Bernelot Moens SJ, Hart LMt, Nijpels G, Dekker JM, Williams KJ, Stroes ESG, van Gaal LF, Staels B, Nieuwdorp M, Dallinga-Thie GM, SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. OBESITY 2014;22 (5):1309-1316 [PubMed]
Khan MT, Nieuwdorp M, Bäckhed F, Microbial Modulation of Insulin Sensitivity. CELL METAB 2014;20 (5):753-760 [PubMed]
Lankelma JM, Nieuwdorp M, de Vos WM, Wiersinga WJ, De darmmicrobiota in gezondheid en ziekte. NED TIJDSCHR GENEESKD 2014;157:A5901 [PubMed]
Mooij HL, Cabrales P, Bernelot Moens SJ, Xu D, Udayappan SD, Tsai AG, van der Sande MAJ, de Groot E, Intaglietta M, Kastelein JJP, Dallinga-Thie GM, Esko JD, Stroes ES, Nieuwdorp M, Loss of function in heparan sulfate elongation genes EXT1 and EXT 2 results in improved nitric oxide bioavailability and endothelial function. J AM HEART ASSOC 2014;3 (6):e001274 [PubMed]
Nieuwdorp M, Faecal microbiota transplantation. BRIT J SURG 2014;101 (8):887-888 [PubMed]
Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM, Role of the microbiome in energy regulation and metabolism. GASTROENTEROLOGY 2014;146 (6):1525-1533 [PubMed]
Samocha-Bonet D, Dixit VD, Kahn CR, Leibel RL, Lin X, Nieuwdorp M, Pietiläinen KH, Rabasa-Lhoret R, Roden M, Scherer PE, Klein S, Ravussin E, Metabolically healthy and unhealthy obese - the 2013 Stock Conference report. OBES REV 2014;15 (9):697-708 [PubMed]
Sanders ME, Lenoir-Wijnkoop I, Salminen S, Merenstein DJ, Gibson GR, Petschow BW, Nieuwdorp M, Tancredi DJ, Cifelli CJ, Jacques P, Pot B, Probiotics and prebiotics: prospects for public health and nutritional recommendations. ANN NY ACAD SCI 2014;1309:19-29 [PubMed]
Singh R, Nieuwdorp M, ten Berge IJM, Bemelman FJ, Geerlings SE, The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. CLIN MICROBIOL INFEC 2014;20 (11):1119-1125 [PubMed]
Singh R, van Nood E, Nieuwdorp M, van Dam B, ten Berge IJM, Geerlings SE, Bemelman FJ, Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. CLIN MICROBIOL INFEC 2014;20 (11):O977-O978 [PubMed]
Udayappan SD, Hartstra AV, Dallinga-Thie GM, Nieuwdorp M, Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. CLIN EXP IMMUNOL 2014;177 (1):24-29 [PubMed]
van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, Dutt C, Chauthaiwale V, Ackermans M, Nederveen A, Serlie M, Nieuwdorp M, Stroes E, The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLOS ONE 2014;9 (2):e86890 [PubMed]
van der Valk FM, Kroon J, Potters WV, Thurlings RM, Bennink RJ, Verberne HJ, Nederveen AJ, Nieuwdorp M, Mulder WJM, Fayad ZA, van Buul JD, Stroes ESG, In vivo imaging of enhanced leukocyte accumulation in atherosclerotic lesions in humans. J AM COLL CARDIOL 2014;64 (10):1019-1029 [PubMed]
van Nood E, Speelman P, Nieuwdorp M, Keller J, Fecal microbiota transplantation: facts and controversies. CURR OPIN GASTROEN 2014;30 (1):34-39 [PubMed]
Vinjé S, Stroes E, Nieuwdorp M, Hazen SL, The gut microbiome as novel cardio-metabolic target: the time has come!. EUR HEART J 2014;35 (14):883-887 [PubMed]
Vrieze A , Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, van Nood E, Holleman F, Knaapen M, Romijn JA, Soeters MR, Blaak EE, Dallinga-Thie GM, Reijnders D, Ackermans MT, Serlie MJ, Knop FK, Holst JJ, van der Ley C, Kema IP, Zoetendal EG, de Vos WM, Hoekstra JBL, Stroes ES, Groen AK, Nieuwdorp M, Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J HEPATOL 2014;60 (4):824-831 [PubMed]
Bernelot Moens SJ, Hassing CH, Nieuwdorp M, Stroes ESG, Dallinga-Thie GM, Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. CLIN LIPIDOL 2013;8 (3):321-328
de Vos WM, Nieuwdorp M, Genomics: A gut prediction. NATURE 2013;498 (7452):48-49 [PubMed]
Hassing HC. Glycobiology in cardiometabolic homeostasis. s.l.: s.n.; 2013. 227p. ISBN 978946191735578 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Stroes ESG; copromotor(s): Nieuwdorp M, Dallinga-Thie GM)
Knaapen M, Kootte RS, Zoetendal EG, de Vos WM, Dallinga-Thie GM, Levi M, Stroes ES, Nieuwdorp M, Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?. CLIN MICROBIOL INFEC 2013;19 (4):331-337 [PubMed]
Mulders TA, Nieuwdorp M, Stroes ES, Vink H, Pinto-Sietsma SJ, Non-invasive assessment of microvascular dysfunction in families with premature coronary artery disease. INT J CARDIOL 2013;168 (5):5026-5028 [PubMed]
Nieuwdorp M, Vrieze A , de Vos WM, Reply to Konstantinov and Peppelenbosch. GASTROENTEROLOGY 2013;144 (4):e20-e21 [PubMed]
Scicluna BP, van 't Veer C, Nieuwdorp M, Felsmann K, Wlotzka B, Stroes ESG, van der Poll T, Role of tumor necrosis factor-α in the human systemic endotoxin-induced transcriptome. PLOS ONE 2013;8 (11):e79051 [PubMed]
Smits LP, Bouter KEC, de Vos WM, Borody TJ, Nieuwdorp M, Therapeutic potential of fecal microbiota transplantation. GASTROENTEROLOGY 2013;145 (5):946-953 [PubMed]
Sondermeijer BM, Battjes S, van Dijk TH, Ackermans MT, Serlie MJ, Nieuwdorp M, Groen AK, Dallinga-Thie GM, Stroes ESG, Lactate increases hepatic secretion of VLDL-triglycerides in humans. ATHEROSCLEROSIS 2013;228 (2):443-450 [PubMed]
van Nood E, Vrieze A , Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ, Duodenal infusion of donor feces for recurrent Clostridium difficile. NEW ENGL J MED 2013;368 (5):407-415 [PubMed]
Vrieze A. The role of gut microbiota in human metabolism. s.l.: s.n.; 2013. 201p. ISBN 9789461084040 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Hoekstra JBL, de Vos WM; copromotor(s): Nieuwdorp M, Holleman F)
Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, Nieuwdorp M, Fecal transplant: A safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?. BEST PRACT RES CL GA 2013;27 (1):127-137 [PubMed]
Hassing HC, Mooij H, Guo S, Monia BP, Chen K, Kulik W, Dallinga-Thie GM, Nieuwdorp M, Stroes ESG, Williams KJ, Inhibition of hepatic sulfatase-2 In Vivo: A novel strategy to correct diabetic dyslipidemia. HEPATOLOGY 2012;55 (6):1746-1753 [PubMed]
Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM, Pathophysiology of hypertriglyceridemia. BBA-MOL CELL BIOL L 2012;1821 (5):826-832 [PubMed]
Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JBL, Stroes ES, Nieuwdorp M, The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. DIABETES OBES METAB 2012;14 (2):112-120 [PubMed]
Lemkes BA, Nieuwdorp M, Hoekstra JBL, Holleman F, The Glycocalyx and Cardiovascular Disease in Diabetes: Should We Judge the Endothelium by Its Cover?. DIABETES TECHNOL THE 2012;14 (1):S3-S10 [PubMed]
Vrieze A , Schopman JE, Admiraal WM, Soeters MR, Nieuwdorp M, Verberne HJ, Holleman F, Fasting and Postprandial Activity of Brown Adipose Tissue in Healthy Men. J NUCL MED 2012;53 (9):1407-1410 [PubMed]
Vrieze A , van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, van Hylckama Vlieg JET, Bloks VW, Groen AK, Heilig HGHJ, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JBL, Nieuwdorp M, Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. GASTROENTEROLOGY 2012;143 (4):913-+ [PubMed]
Broekhuizen LN. Glycocalyx, cardiometabolic disease and inflammation. S.l.: s.n.; 2011. 183p. ISBN 9789461082008 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Kastelein JJP, Vink H; copromotor(s): Stroes ESG, Nieuwdorp M)
Sivapalaratnam S, Farrugia R, Nieuwdorp M, Langford CF, van Beem RT, Maiwald S, Zwaginga JJ, Gusnanto A, Watkins NA, Trip MD, Ouwehand WH, Identification of candidate genes linking systemic inflammation to atherosclerosis; results of a human in vivo LPS infusion study. BMC MED GENOMICS 2011;4:64 [PubMed]
Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ESG, Vink H, Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. DIABETOLOGIA 2010;53 (12):2646-2655 [PubMed]
Cherpanath TGV, Nieuwdorp M, Hazenberg MD, van Eeden S, van der Sluijs AF, Large nocturnal eyes causing gastrointestinal bleeding in asymptomatic multiple myeloma. CMV enterocolitis. NETH J MED 2010;68 (10):324-327 [PubMed]
Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F, Kastelein JJP, Péterfy M, Nieuwdorp M, The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight. ATHEROSCLEROSIS 2010;211 (1):1-8 [PubMed]
Meuwese MC, Broekhuizen LN, Kuikhoven M, Heeneman S, Lutgens E, Gijbels MJJ, Nieuwdorp M, Peutz CJ, Stroes ESG, Vink H, van den Berg BM, Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein e-deficient mice. PLOS ONE 2010;5 (12):e14262 [PubMed]
van Sluis GL, Nieuwdorp M, Kamphuisen PW, van der Vlag J, van Noorden CJF, Spek CA, A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx. PLOS ONE 2010;5 (6):e11200 [PubMed]
Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JBL, Nieuwdorp M, The environment within: how gut microbiota may influence metabolism and body composition. DIABETOLOGIA 2010;53 (4):606-613 [PubMed]
Broekhuizen LN, Mooij HL, Kastelein JJP, Stroes ESG, Vink H, Nieuwdorp M, Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. CURR OPIN LIPIDOL 2009;20 (1):57-62 [PubMed]
Meuwese MC, Mooij HL, Nieuwdorp M, van Lith B, Marck R, Vink H, Kastelein JJP, Stroes ESG, Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J LIPID RES 2009;50 (1):148-153 [PubMed]
Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MHP, Hayden A, Levi M, Meijers JCM, Ince C, Kastelein JJP, Vink H, Stroes ESG, Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. ATHEROSCLEROSIS 2009;202 (1):296-303 [PubMed]
Nieuwdorp M, Nio CY, Bartelsman JFWM, Hoekstra JBL, Intermitting umbilical pain, fever and weight loss in an otherwise healthy 65-year-old male. NETH J MED 2009;67 (8):334-335 [PubMed]
Verkleij CJN , Nieuwdorp M, Gerdes VEA, Mörgelin M, Meijers JCM, Marx PF, The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. THROMB HAEMOSTASIS 2009;102 (3):460-468 [PubMed]
Levi M, Nieuwdorp M, Poll Tvd, Stroes E, Metabolic modulation of inflammation-induced activation of coagulation. SEMIN THROMB HEMOST 2008;34 (1):26-32 [PubMed]
Nieuwdorp M, Meuwese MC, Mooij HL, Ince C, Broekhuizen LN, Kastelein JJP, Stroes ESG, Vink H, Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J APPL PHYSIOL 2008;104 (3):845-852 [PubMed]
Nieuwdorp M, van Nood E, Speelman P, van Heukelem HA, Jansen JM, Visser CE, Kuijper EJ, Bartelsman JFWM, Keller JJ, Behandeling van recidiverende Clostridium dificile-geassocieerde diarree met een suspensie van donorfeces. NED TIJDSCHR GENEESKD 2008;152 (35):1927-1932 [PubMed]
Nieuwdorp M, Vergeer M, Bisoendial RJ, Op 't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJP, Stroes ESG, Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. DIABETOLOGIA 2008;51 (6):1081-1084 [PubMed]
van Beers EJ, Nieuwdorp M, Duits AJ, Evers LM, Schnog JJB, Biemond BJ, Sickle cell patients are characterized by a reduced glycocalyx volume. HAEMATOLOGICA 2008;93 (2):307-308 [PubMed]
Nieuwdorp M. Metabolic and vascular dysfunction during hyperglycemia induced inflammation. The role of the endothelial glycocalyx on vascular homeostasis in vivo. s.l.: s.n.; 2007. 158p. ISBN 9789090221038 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Hoekstra JBL, Kastelein JJP; copromotor(s): Stroes ESG, Vink H)
Nieuwdorp M, Holleman F, de Groot E, Vink H, Gort J, Kontush A, Chapman MJ, Hutten BA, Brouwer CB, Hoekstra JBL, Kastelein JJP, Stroes ESG, Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. DIABETOLOGIA 2007;50 (6):1288-1293 [PubMed]
Nieuwdorp M, Stroes ESG, Kastelein JJP, Normalization of metabolic syndrome using fenofibrate, metformin or their combination. DIABETES OBES METAB 2007;9 (6):869-878 [PubMed]
Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJP, Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. DIABETES OBES METAB 2007;9 (3):218-232 [PubMed]
van den Berg BM, Nieuwdorp M, Stroes ESG, Vink H. Luminal Glycocalyx: protective barrier between endothelial cells and flowing blood. in: Aird WC, editor. Endothelial Biomedicine. Cambridge: Cambridge University Press; 2007., p. -
van Oostrom O, Nieuwdorp M, Westerweel PE, Hoefer IE, Basser R, Stroes ESG, Verhaar MC, Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. ARTERIOSCL THROM VAS 2007;27 (8):1864-1865 [PubMed]
Gouverneur M, Berg B, Nieuwdorp M, Stroes E, Vink H, Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress. J INTERN MED 2006;259 (4):393-400 [PubMed]
Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JAE, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JBL, Kastelein JJP, Stroes ESG, Vink H, Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. DIABETES 2006;55 (4):1127-1132 [PubMed]
Nieuwdorp M, van Haeften TW, Gouverneur MCLG, Mooij HL, van Lieshout MHP, Levi M, Meijers JCM, Holleman F, Hoekstra JBL, Vink H, Kastelein JJP, Stroes ESG, Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. DIABETES 2006;55 (2):480-486 [PubMed]
Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, Trip MD, Kastelein JJP, Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. DIABETES CARE 2006;29 (5):1125-1127 [PubMed]
van den Berg BM, Nieuwdorp M, Stroes ESG, Vink H, Glycocalyx and endothelial (dys) function: from mice to men. PHARMACOL REP 2006;58 (Suppl):75-80 [PubMed]
Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JBL, Kastelein JJP, Stroes ESG, The endothelial glycocalyx: a potential barrier between health and vascular disease. CURR OPIN LIPIDOL 2005;16 (5):507-511 [PubMed]
Nieuwdorp M, Stroes ESG, Meijers JCM, Büller H, Hypercoagulability in the metabolic syndrome. CURR OPIN PHARMACOL 2005;5 (2):155-159 [PubMed]
Key publications

Vrieze A , van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, van Hylckama Vlieg JET, Bloks VW, Groen AK, Heilig HGHJ, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JBL, Nieuwdorp M, Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. GASTROENTEROLOGY 2012;143 (4):913-+ [PubMed]
de Vos WM, Nieuwdorp M, Genomics: A gut prediction. NATURE 2013;498 (7452):48-49 [PubMed]
van Nood E, Vrieze A , Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ, Duodenal infusion of donor feces for recurrent Clostridium difficile. NEW ENGL J MED 2013;368 (5):407-415 [PubMed]
Smits LP, Bouter KEC, de Vos WM, Borody TJ, Nieuwdorp M, Therapeutic potential of fecal microbiota transplantation. GASTROENTEROLOGY 2013;145 (5):946-953 [PubMed]
Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P, Durable coexistence of donor and recipient strains after fecal microbiota transplantation. SCIENCE 2016;352 (6285):586-589 [PubMed]


All Publications

Curriculum Vitae

2002 MD (Utrecht University)

 

2007 PhD (AMC-Univerisity of Amsterdam,promotor: Prof J.J.P. Kastelein)

 

2007-2008 Postdoctoral fellow University of California San Diego (Glycobiology research center, prof J. Esko)

2008 VENI-ZONMW grant

2012 Registration Internist-Endocrinologist

 

2012-  Associate professor Vascular Medicine

 

2013- Visiting Professor Sahlgrenska University Hospital, Gothenborg University (Prof F. Backhed)

 

2014- Director Laboratory of Experimental Vascular Medicine, AMC-UvA

 

2014 VIDI-ZONMW grant

2015 Professor Internal Medicine  AMC-UvA

 

Research programmes

Gutmicrobiota as novel diagnostic and therapeutic targets in cardiometabolism

Our group focuses on the role of intestinal microbiota in chronic inflammation and human cardiometabolism in a translational fashion. We aim to find novel pathophysiological pathways driving cardiovascular disease, dyslipidemia and diabetes mellitus studying the role of baceria in adipose tissue, liver (NASH) and macrovascular inflammation. In line, we will try to identify novel therapeutic targets via identifying bacterial ligands or developing novel probiotic bacterial strains and vaccination leads to treat these diseases.

Faculty
Prof. dr. M. Nieuwdorp MD PhD
Dr. ir. G.M. Dallinga-Thie PhD
Prof. dr. A.K. Groen
Dr. J.H.M. Levels PhD
Prof. dr. N.A.W. van Riel (Eindhoven University of Technology)
Prof. dr. E.S.G. Stroes MD PhD

Postdocs
M. Deschasaux PhD
H.J. Herrema PhD
E. Levin PhD
A. Prodan PhD

PhD Students
O. Aydin
Drs. G.J. Bakker MD
Drs. K.E.C. Bouter
N.C. de Clercq
Drs. P.W. Gilijamse
Drs. P.F. de Groot
Drs. A.V. Hartstra MD
Drs. K.W. ter Horst MD
A.M. Koopen
Drs. R.S. Kootte
A.S. Meijnikman
Drs. C.C. van Olden
Drs. L.P. Smits
Drs. R.P. Surendran
Drs. S.D. Udayappan
M. van Baar MD (VUMC)
E. Van Bommel MD (VUMC)
K. Fluitman (VUMC)
T. Scheithauer MSc (VUmc)

Prof. dr. E.S.G. Stroes MD PhD (Novel anti-atherogenic strategies targeting the vessel wall)

Other research related activities
  • Membership of medical or scientific committee, University of Amsterdam, Medical Ethics Committee, AMC
Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • AstraZeneca BV
  • Caelus Pharmaceuticals B.V.
  • Eli Lilly Nederland BV
  • Europese Unie
  • Nederlandse Hartstichting
  • Stichting AMC Foundation (Vrijgesteld)
  • The Novo Nordisk Foundation Center
  • ZonMw